CSL Limited CSLLY
Set alert
34.69 USD -0.66 -1.87%
As of Nov 3, 11:48 AM ET
34.69 Day range 34.77
16.01 52-week range 35.64
- YTD
- +20.45%
- 1 year
- +21.46%
- Open
- 34.75
- Prev close
- 35.35
- Mkt cap
- 66.59B
- Vol
- 500
- Avg vol
- 91.86K
- EPS
- -1.34
- P/E
- 0.00
More statistics
- Low
- 34.69
- High
- 34.77
2Y chart
Events in this range
- Feb 10, 2025Earnings: 0.2594; estimate —; surprise —%
- Mar 11, 2025Dividend: 0.65
- Sep 10, 2025Dividend: 0.81
- Feb 10, 2026Earnings: 0.055; estimate —; surprise —%
- Mar 2, 2026Split: 2 for 1
- Mar 11, 2026Dividend: 0.31922
- Sep 10, 2026Dividend: 0.39051
Signals (70)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 27, 2026 | 1 week ago |
| RSI: Overbought | Oct 19, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 16, 2026 | 2 weeks ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| RSI: Overbought | Aug 18, 2026 | 2 months ago |
| RSI: Overbought | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 30, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 21, 2026 | 3 months ago |
| RSI: Overbought | Jul 9, 2026 | 3 months ago |
| RSI: Overbought | Jul 6, 2026 | 4 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| RSI: Oversold | May 11, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 22, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 23, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 20, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 10, 2026 | 7 months ago |
| RSI: Oversold | Mar 6, 2026 | 8 months ago |
| RSI: Oversold | Mar 3, 2026 | 8 months ago |
Newest 20 of 70.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2026 | Dec 31, 2025 | — | 0.055 | — | — |
| Feb 10, 2025 | Dec 31, 2024 | — | 0.2594 | — | — |
News
- CSL Limited (CSLLY) Shareholder/Analyst Call Transcript
- CSL appoints Deborah Waterhouse as CEO & Managing Director
- Australia's CSL appoints Deborah Waterhouse as CEO
- HRMY vs. CSLLY: Which Stock Is the Better Value Option?
- CSL y Alentis desarrollarán y comercializarán lixudebart para enfermedades renales y hepáticas raras
- CSL strikes US$1.6 billion licensing deal for rare disease drug
- CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis
- CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
- Australia's CSL taps Amazon's cloud unit to boost research pipeline
- Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults
Your note
Sign in to keep a note on CSLLY — it syncs with the Stock Master app.